Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Raw Materials (2016 - 2025)

Ocular Therapeutix has reported Raw Materials over the past 11 years, most recently at $202000.0 for Q4 2025.

  • Quarterly results put Raw Materials at $202000.0 for Q4 2025, down 5.61% from a year ago — trailing twelve months through Dec 2025 was $202000.0 (down 5.61% YoY), and the annual figure for FY2025 was $202000.0, down 5.61%.
  • Raw Materials for Q4 2025 was $202000.0 at Ocular Therapeutix, down from $229000.0 in the prior quarter.
  • Over the last five years, Raw Materials for OCUL hit a ceiling of $388000.0 in Q4 2021 and a floor of $187000.0 in Q1 2025.
  • Median Raw Materials over the past 5 years was $305500.0 (2022), compared with a mean of $288400.0.
  • Biggest five-year swings in Raw Materials: surged 86.5% in 2021 and later plummeted 43.16% in 2025.
  • Ocular Therapeutix's Raw Materials stood at $388000.0 in 2021, then fell by 20.36% to $309000.0 in 2022, then dropped by 2.27% to $302000.0 in 2023, then decreased by 29.14% to $214000.0 in 2024, then fell by 5.61% to $202000.0 in 2025.
  • The last three reported values for Raw Materials were $202000.0 (Q4 2025), $229000.0 (Q3 2025), and $219000.0 (Q2 2025) per Business Quant data.